Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Catherine Belle Meador, M.D.

Concepts (83)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Drug Resistance, Neoplasm9202049380.960 Why?
Leadership2201611350.710 Why?
Molecular Targeted Therapy3202027160.580 Why?
Lung Neoplasms92020112170.520 Why?
Biomedical Research2201630940.440 Why?
Proto-Oncogene Proteins B-raf2201517640.380 Why?
MAP Kinase Signaling System2201515790.380 Why?
Antineoplastic Agents52020136310.360 Why?
Mutation82017276080.320 Why?
Negotiating220161190.310 Why?
Acrylamides320172320.310 Why?
Protein Kinase Inhibitors5201650610.310 Why?
Carcinoma, Non-Small-Cell Lung2202041900.300 Why?
Neoplasms32019175870.300 Why?
Small Cell Lung Carcinoma220193190.300 Why?
Education, Medical1201615590.300 Why?
Education, Medical, Graduate1201619460.280 Why?
Genotype22019129640.270 Why?
Aniline Compounds320178430.250 Why?
Tumor Microenvironment2202018050.210 Why?
Paraneoplastic Syndromes, Nervous System12019240.210 Why?
Career Choice220166720.210 Why?
Genetic Variation1201464670.190 Why?
Quinazolines2201515000.180 Why?
Focal Adhesion Protein-Tyrosine Kinases120171830.170 Why?
Colorectal Neoplasms1201558150.170 Why?
Receptor, EphA212016430.160 Why?
Mice, Nude4201741180.160 Why?
Group Processes120162410.150 Why?
Lymphocytes, Tumor-Infiltrating120198430.140 Why?
src-Family Kinases120175980.140 Why?
Curriculum2201628030.140 Why?
Niacinamide120164480.140 Why?
INDEL Mutation120132530.130 Why?
Professional Competence120164910.120 Why?
Benzamides1201612010.110 Why?
Cell Lineage1202027420.110 Why?
DNA, Neoplasm1201518760.100 Why?
Cell Line, Tumor52016168250.090 Why?
Antineoplastic Combined Chemotherapy Protocols32017103480.090 Why?
Receptor Protein-Tyrosine Kinases1201415870.080 Why?
Piperazines1201725020.080 Why?
Humans1420206396930.080 Why?
Protein-Tyrosine Kinases1201524430.080 Why?
Genome, Human2201544000.070 Why?
Animals720201696020.070 Why?
Biopsy1201565710.070 Why?
Cell Transformation, Neoplastic1201431120.070 Why?
Neoplasm Recurrence, Local2201777600.060 Why?
Genetic Testing1201429950.060 Why?
Cell Proliferation22016111100.060 Why?
Genomics1201444110.050 Why?
Adenocarcinoma1201564270.040 Why?
Melanoma1201452190.040 Why?
Treatment Outcome22020576010.040 Why?
Survival Rate22019130850.030 Why?
Drug Screening Assays, Antitumor120158030.030 Why?
Drug Synergism1201619490.030 Why?
Benzimidazoles120158270.030 Why?
Aged320191542130.030 Why?
Drug Evaluation, Preclinical1201515130.030 Why?
ras Proteins1201511620.020 Why?
Mice42017798160.020 Why?
Proto-Oncogene Proteins p21(ras)1201515580.020 Why?
Signal Transduction32017241740.020 Why?
Transfection1201765900.020 Why?
Xenograft Model Antitumor Assays1201636840.020 Why?
DNA Copy Number Variations1201316050.020 Why?
Drug Therapy, Combination1201565180.020 Why?
Male320193395760.020 Why?
Longitudinal Studies12017125380.020 Why?
High-Throughput Nucleotide Sequencing1201331570.010 Why?
Sequence Analysis, DNA1201350750.010 Why?
Prognosis12019272350.010 Why?
Apoptosis12016104690.010 Why?
Follow-Up Studies12017384650.010 Why?
Female320193592290.010 Why?
Prospective Studies12017454860.010 Why?
Middle Aged220192081870.010 Why?
Polymorphism, Single Nucleotide12013150770.010 Why?
Retrospective Studies12019587940.010 Why?
Aged, 80 and over12017571540.010 Why?
Adult120172027640.000 Why?
Meador's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (83)
Co-Authors (18)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.